Potential contribution of SIM2 and ETS2 functional polymorphisms in Down syndrome associated malignancies

BMC Medical Genetics

Kanchan Mukhopadhyay⁶  Ananda L Roy²  Keya Chaudhuri³  Chinmay Kumar Panda⁴  Swagata Sinha⁶  Ashis Mukherjee⁵  Avirup Dutta³  Nupur Mukherjee⁴  Sanjit Mukherjee³  Samikshan Dutta¹  Arpita Chatterjee⁶ 

[1]Present address: Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Nebraska, USA

[2]Tufts University School of Medicine, Boston, MA, USA

[3]Indian Institute of Chemical Biology, Kolkata, India

[4]Chittaranjan National Cancer Institute, Kolkata, India

[5]Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, India

[6]Manovikas Biomedical Research and Diagnostic Centre, MRIH, 482, Madudah, Plot I-24, Sec.-J, E.M. Bypass, Kolkata, 700107, India

关键词: Acute lymphoblastic leukemia;    Oral cancer;    Breast cancer;    Down syndrome;    ETS2;    SIM2;   

Others  :  1177743
DOI  :  10.1186/1471-2350-14-12

 received in 2012-02-06, accepted in 2013-01-18,  发布年份 2013

【 摘 要 】

Background

Proper expression and functioning of transcription factors (TFs) are essential for regulation of different traits and thus could be crucial for the development of complex diseases. Subjects with Down syndrome (DS) have a higher incidence of acute lymphoblastic leukemia (ALL) while solid tumors, like breast cancer (BC) and oral cancer (OC), show rare incidences. Triplication of the human chromosome 21 in DS is associated with altered genetic dosage of different TFs. V-ets erythroblastosis virus E26 oncogene homolog 2 (ETS2) and Single Minded 2 (SIM2) are two such TFs that regulate several downstream genes involved in developmental and neurological pathways. Here we studied functional genetic polymorphisms (fSNP) in ETS2 and SIM2 encoding genes in a group of patients and control subjects to better understand association of these variants with DS phenotypes.

Methods

We employed an in silico approach to identify potential target pathways of ETS2 and SIM2. fSNPs in genes encoding for these two TFs were identified using available databases. Selected sites were genotyped in individuals with DS, their parents, ALL, BC, OC as well as ethnically matched control individuals. We further analyzed these data by population-based statistical methods.

Results

Allelic/genotypic association analysis showed significant (P < 0.03) differences of rs2070530, rs1051476, rs11254, rs711 for DS subjects compared to control. rs711 also exhibited significantly different genotypic distribution pattern in parents of DS probands (P < 0.02) and BC patients (P < 0.02). Interaction analysis revealed independent main effect of rs711 in all the groups, while rs11254 exhibited independent main effect in DS subjects only. High entropy values were noticed for rs461155 in the solid tumor groups. Significant interactive effects of rs2070531 with rs1051475, rs1051476, rs11254 were observed in all the groups except DS.

Conclusions

We infer from the present investigation that the difference in frequencies of fSNPs and their independent as well as interactive effects may be the cause for altered expression of SIM2 and ETS2 in DS and malignant groups, which affects different downstream biological pathways. Thus, altered expression of SIM2 and ETS2 could be one of the reasons for variable occurrence of different malignant conditions in DS.

【 授权许可】

   
2013 Chatterjee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Hasle H, Clemmensen IH, Mikkelsen M: Risks of leukemia and solid tumors in individuals with Down’s syndrome. Lancet 2000, 355:165-169.
• [2]Chen R, Morgan AA, Dudley J, Deshpande T, Li L, Kodama K, Chiang AP, Butte AJ: FitSNPs: highly differentially expressed genes are more likely to have variants associated with disease. Genome Biol 2008, 9:R170. BioMed Central Full Text
• [3]Michaud J, Fan CM: Single-minded-two genes, three chromosomes. Genome Res 1997, 7:569-571.
• [4]Yamaki A, Noda S, Kudoh J, Shindoh N, Maeda H, Minoshima S, Kawasaki K, Shimizu Y, Shimizu N: The mammalian single-minded (SIM) gene: mouse cDNA structure and diencephalic expression indicate a candidate gene for Down syndrome. Genomics 1996, 35:136-143.
• [5]Wharton KA Jr, Franks RG, Kasai Y, Crews ST: Control of CNS midline transcription by asymmetric E-box-like elements: similarity to xenobiotic responsive regulation. Development 1994, 120:3563-3569.
• [6]Rushmore TH, Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II drugmetabolizing enzymes. Curr Drug Metab 2002, 3:481-490.
• [7]Hankinson O: The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995, 35:307-340.
• [8]Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP: Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 2000, 59:65-85.
• [9]Young MPD, Tress M, Narayanan R: Identification of Down’s syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors. Proc Natl Acad Sci 2003, 100:4760-4765.
• [10]Aleman MJ, Young MPD: Inhibition of single minded 2 gene expression mediates tumor-selective apoptosis and differentiation in human colon cancer cells. Proc Natl Acad Sci 2005, 102:12765-12770.
• [11]Halvorsen OJ, Oyan AM, Bo TH, Olsen S, Rostad K, Haukaas SA, Bakke AM, Marzolf B, Dimitrov K, Stordrange L, Lin B, Jonassen I, Hood L, Akslen LA, Kalland KH: Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. Int J Oncol 2005, 26:329-336.
• [12]Kwak HI, Gustafson T, Metz RP, Laffin B, Schedin P, Porter WW: Inhibition of breast cancer growth and invasion by single-minded 2 s. Carcinogenesis 2007, 28(2):259-266.
• [13]Rosa-Rosa JM, Pita G, Urioste M, Llort G, Brunet J, Lázaro C, Blanco I, Ramón Y, Cajal T, Díez O, de la Hoya M, Caldés T, Tejada MI, González-Neira A, Benítez J: Genome-wide linkage scan reveals three putative breast-cancer-susceptibility loci. Am J Hum Genet 2009, 84:115-122.
• [14]Sumarsono SH, Wilson TJ, Tymms MJ, Venter DJ, Corrick CM, Kola R, Lahoud MH, Papas TS, Seth A, Kola I: Down’s syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nat London 1996, 379:534-538.
• [15]Wolvetang EJ, Bradfield OM, Hatzistavrou T, Crack PJ, Busciglio J, Kola I, Hertzog PJ: Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis. Neurobiol Dis 2003, 14:349-356.
• [16]Wolvetang EW, Bradfield OM, Tymms M, Zavarsek S, Hatzistavrou T, Kola I, Hertzog PJ: The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome. Biochim Biophys Acta 2003, 1628:105-110.
• [17]Watson DK, Ascione R, Papas TS: Molecular analysis of the ets genes and their products. Crit Rev Oncog 1990, 1:409-436.
• [18]Seth A, Ascione R, Fisher RJ, Mavrothalassitis GJ, Bhat NK, Papas TS: The ets gene family. Cell Growth Differ 1992, 3:327-334.
• [19]Macleod K, Leprince D, Stehelin D: The ets gene family. Trends Biochem Sci 1992, 17:251-256.
• [20]Wasylyk B, Hahn SL, Giovane A: The Ets family of transcription factors. Eur J Biochem 1993, 211:7-18.
• [21]Ghysdael J, Boureux A: The ETS family of Transcriptional regulators. In In The ETS family of Transcriptional regulators.. Volume 1 edition. Edited by Yaniv M, Ghysdael J. Switzerland: Birkhauser Verlag: Basel; 1997:29-88.
• [22]Dittmer J, Nordheim A: Ets trsnscription factor and human disease. Biochim Biophys Acta 1998, 1377:F1-F11.
• [23]Papas TS, Bhat NK, Spyropoulos DD, Mjaatvedt AE, Vournakis J, Seth A, Watson DK: Functional relationships among ETS gene family members. Leukemia 1997, 11(Suppl 3):557-566.
• [24]Ghosh A, Kolodkin AL: Specification of neuronal connectivity: ETS marks the spot. Cell 1998, 95:303-306.
• [25]Karim FD, Urness LD, Thummel CS, Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA, Gunther CV, Nye JA, Graves BJ: The ETS-domain: a new DNA-binding motif that recognizes a purine-rich core DNA sequence. Genes Dev 1990, 4:1451-1453.
• [26]Sharrocks AD, Brown AL, Ling Y, Yates PR: The ETS-domain transcription factor family. Int J Biochem Cell Biol 1997, 29:1371-1387.
• [27]Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV: Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucl Acids Res 2004, 32:4358-4367.
• [28]Sementchenko VI, Watson DK: Ets target genes: past, present and future. Oncogene 2000, 19:6533-6548.
• [29]Baker KM, Wei G, Schaffner AE, Ostrowski MC: Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter. J Biol Chem 2003, 278:17876-17884.
• [30]Papas TS, Watson DK, Sacchi N, Fujiwara S, Seth AK, Fisher RJ, Bhat NK, Mavrothalassitis G, Koizumi S, Jorcyk CL, et al.: ETS family of genes in leukemia and Down syndrome. Am J Med Genet 1990, 7:251-261.
• [31]Stankiewicz MJ, Crispino JD: ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 2009, 113:1347-3337.
• [32]Chatterjee A, Dutta S, Mukherjee S, Mukherjee N, Chandra S, Mukherjee A, Sinha S, Panda CK, Chaudhuri K, Mukhopadhyay K: Differential allelic distribution of V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2) functional polymorphisms in different group of patients. Gene Express 2011, 15:61-73.
• [33]Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 1988, 16:1215.
• [34]Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, Sham PC: PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 2007., 81http://pngu.mgh.harvard.edu/~purcell/plink/contact.shtml webcite
• [35]Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25(2):115-121.
• [36]Mei H, Ma D, Ashley-Koch A, Martin ER: Extension of multifactor dimensionality reduction for identifying multilocus effects in the GAW14 simulated data. BMC Genet 2005, 6:S145-S149. BioMed Central Full Text
• [37]Lenth RV: Statistical power calculations. J Anim Sci 2007, 85:E24-E29.
• [38]Chatterjee A, Dutta S, Sinha S, Mukhopadhyay K: Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome. Disease Markers 2011, 31:247-257.
• [39]Zenger S, He W, Ek-Rylander B, Vassiliou D, Wedin R, Bauer H, Andersson G: Differential expression of tartrate-resistant acid phosphatase isoforms 5a and 5b by tumor and stromal cells in human metastatic bone disease. Clin Exp Metastasis 2011, 28(1):65-73.
• [40]Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP: The human KLK8 (neuropsin/ovasin) gene: identification of Two novel splice variants and its prognostic value in ovarian cancer. Clin Can Res 2001, 7:806-811.
• [41]Mao R, Wang X, Spitznagel EL Jr, Frelin LP, Ting JC, Ding H, Kim JW, Ruczinski I, Downey TJ, Pevsner J: Primary and secondary transcriptional effects in the developing human down syndrome brain and heart. Genome Biol 2005, 6(13):R107. BioMed Central Full Text
• [42]Deutsch S, Lyle R, Dermitzakis ET, Attar H, Subrahmanyan L, Gehrig C, Parand L, Gagnebin M, Rougemont J, Jongeneel CV, Antonarakis SE: Gene expression variation and expression quantitative trait mapping of human chromosome 21 genes. Hum Mol Genet 2005, 14(23):3741-3749.
• [43]Conti A, Fabbrini F, D’Agostino P, Negri R, Greco D, Genesio R, D’Armiento M, Olla C, Paladini D, Zannini M, Nitsch L: Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics 2007, 8:268. BioMed Central Full Text
• [44]Sommer CA, Pavarino-Bertelli EC, Goloni-Bertollo EM, Henrique-Silva F: Identification of dysregulated genes in lymphocytes from children with down syndrome. Genome 2008, 51:19-29.
• [45]Lockstone HE, Harris LW, Swatton JE, Wayland MT, Holland AJ, Bahn S: Gene expression proWling in the adult down syndrome brain. Genomics 2007, 90:647-660.
• [46]Altug-Teber O, Bonin M, Walter M, Mau-Holzmann UA, Dufke A, Stappert H, Tekesin I, Heilbronner H, Nieselt K, Riess O: SpeciWc transcriptional changes in human fetuses with autosomal trisomies. Cytogenet Genome Res 2007, 119:171-184.
• [47]Patterson D: Molecular genetic analysis of down syndrome. Hum Genet 2009, 126:195-214.
• [48]Rhodes DR, Yu J, Shankerz K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandeyband A, Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6. available at: https://www.oncomine.org/resource/login.html webcite
• [49]Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, de Rijn MV, Waltham M, Pergamenschikov A, Lee JCF, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24(3):227-234.
• [50]Mart’ınez A, Olarte I, Mergold MA, Gutierrez M, Rozen E, Collazo J, Amancio-Chassin O, Ordo’nez RM, Montesinos JJ, Mayani H, McCurdy DK, Ostrosky-Wegman P, Garrido-Guerrero E, Miranda EI: mRNA expression of MAGE-A3 gene in leukemia cells. Leukemia Res 2007, 31:33-37.
• [51]Kuraya M, Matsushita M, Endo Y, Thiel S, Fujita T: Expression of H‐ficolin/Hakata antigen, mannose‐binding lectin‐associated serine protease (MASP)‐1 and MASP‐3 by human glioma cell line T98G. Int Immunol 2003, 15(1):109-117.
• [52]Richards KS, Bommert K, Szabo G, Miles R: Differential expression of Na+/K + −ATPase alpha-subunits in mouse hippocampal interneurones and pyramidal cells. J Physiol 2007, 585(Pt 2):491-505.
• [53]Zhou ZQ, Cao WH, Xie JJ, Lin J, Shen ZY, Zhang QY, Shen JH, Xu LY, Li EM: Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer 2009, 9:291. BioMed Central Full Text
• [54]Lee IK, Choi JH, Kim YK, Kim HN, Park KS, Lee JJ, Shin MG, Choi C, Kook H, Hwang TJ: Two single nucleotide polymorphisms of the ETS2 transcriptional factor gene predispose individuals to high-risk acute myelogenous leukemia AML. Blood ASH Annual Meet Abstrac No. 2729 2005., 106
• [55]Wang Z-J, Churchman M, Campbell IG, Xu W-H, Yan Z-Y, McCluggage WG, Foulkes WD, Tomlinson IPM: Allele loss and mutation screen at the peutz-jeghers (LKB1) locus (19p13.3) In sporadic ovarian tumours. Br J Cancer 1999, 80(1/2):70-72.
• [56]Powierska-Czarny J, Miścicka-Śliwka D, Czarny J, Grzybowski T, Woźniak M, Drewa G, Czechowicz W, Sir J: Analysis of microsatellite instability and loss of heterozygosity in breast cancer with the use of a well characterized multiplex system. Acta Biochimica Polonica 2003, 50:1195-1203.
• [57]Fan CY, Liu KL, Huang HY, Barnes EL, Swalsky PA, Bakker A, Woods J, Finkelstein SD: Frequent allelic imbalance and loss of protein expression of the DNA repair gene hOGG1 in head and neck squamous cell carcinoma. Lab Investig 2001, 81:1429-1438.
• [58]Clayton RN, Pfeifer M, Atkinson AB, Belchetz P, Wass JA, Kyrodimou E, Vanderpump M, Simpson D, Bicknell J, Farrell WE: Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res 2000, 6:3973-3982.
• [59]Sweetser DA, Chen CS, Blomberg AA, Flowers DA, Galipeau PC, Barrett MT, Heerema NA, Buckley J, Woods WG, Bernstein ID, Reid BJ: Loss of heterozygosity in childhood de novo acute myelogenous leukemia. Blood 2001, 98:1188-1194.
• [60]Fonatsch C: The role of chromosome 21 in hematology and oncology. Genes Chromosomes Cancer 2010, 49:497-508.
• [61]Zwaan MC, Reinhardt D, Hitzler J, Vyas P: Acute leukemias in children with down syndrome. Pediatr Clin North Am 2008, 55:53-70.
• [62]Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, Hewitt CA, Scott HS: Hematopoietic defects in the Ts1Cje mouse model of down syndrome. Blood 2009, 113:1929-1937.